Isomorphic Labs Unveils Proprietary Drug-Discovery AI Model IsoDDE

Isomorphic Labs, a biopharmaceutical spin-off of Google DeepMind based in London, has announced the launch of its proprietary artificial intelligence model, IsoDDE, designed to enhance drug discovery. Released on February 10, the model boasts advanced capabilities in predicting how proteins interact with potential therapeutic molecules, marking a significant advancement in the field comparable to the anticipated AlphaFold4.

Nature

IsoDDE's technical report highlights its superior performance in predicting drug–protein interactions and antibody structures, which are crucial for developing effective therapies. Unlike its predecessor, AlphaFold3, which was made publicly accessible, IsoDDE remains proprietary, limiting insights into its methodologies. This has raised concerns among researchers about the transparency and reproducibility of its findings.

Nature

The IsoDDE model reportedly outperforms both Boltz-2, an open-source model developed by researchers at the Massachusetts Institute of Technology, and traditional physics-based methods in determining binding affinity—the strength of drug interactions with proteins. This capability is essential for therapeutic development and is typically assessed through computationally intensive techniques.

Nature

Mohammed AlQuraishi, a computational biologist at Columbia University, has expressed admiration for IsoDDE's ability to predict interactions involving molecules that differ significantly from its training data. He noted, “That’s the really hard problem, and suggests that they must’ve done something pretty novel.” This sentiment underscores the model's potential impact on drug discovery.

Nature

Despite the excitement surrounding IsoDDE, its proprietary nature has drawn criticism from the scientific community. Many researchers advocate for open-source models, like AlphaFold, which have democratized access to advanced predictive tools. AlQuraishi, who is working on developing open-source alternatives, emphasizes the importance of transparency in scientific advancements, stating, “The problem, of course, is that we know nothing of the details.”

Nature

The introduction of IsoDDE by Isomorphic Labs represents a significant milestone in the field of drug discovery, showcasing advanced predictive capabilities that could transform therapeutic development. However, the proprietary nature of the model raises important questions about accessibility and transparency in scientific research, prompting ongoing discussions within the community about the balance between innovation and open collaboration.

Nature